Terminology Service for NFDI4Health
VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593
Go to external page
http://purl.obolibrary.org/obo/NCIT_C79794
An oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity. TAK-593 selectively binds to and inhibits VEGFR and PDGFR, which may result in the inhibition of angiogenesis and tumor cell proliferation. [ ]
Term info
Label
VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593
Synonyms
- TAK-593
- VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593
Subsets
NCIT_C116978, NCIT_C128784, NCIT_C116977, NCIT_C157711, NCIT_C157712
Contributing Source
CTRP
Display Name
VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593
Legacy Concept Name
VEGFR_PDGFR_Tyrosine_Kinase_Inhibitor_TAK-593
PDQ Closed Trial Search ID
618858
PDQ Open Trial Search ID
618858
Preferred Name
VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593
Semantic Type
Pharmacologic Substance
UMLS CUI
C2703162
code
C79794
Term relations
Subclass of:
- Antineoplastic Enzyme Inhibitor
- VEGFR Tyrosine Kinase Inhibitor
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Receptor Tyrosine Kinase Inhibition
- Chemical_Or_Drug_Has_Physiologic_Effect some Inhibition of Cell Proliferation
- Chemical_Or_Drug_Has_Physiologic_Effect some Signal Transduction Inhibition
- Chemical_Or_Drug_Has_Physiologic_Effect some Positive Regulation of Apoptosis